tradingkey.logo

CytoMed Therapeutics To Start Dose Level 2 In Angelica Trial Q3 2025

ReutersJul 21, 2025 3:52 PM

- CytoMed Therapeutics Ltd F98.F:

  • UPDATE ON CLINICAL TRIAL MILESTONE - CYTOMED THERAPEUTICS ACHIEVES COMPLETION OF DOSE LEVEL 1 OF ITS ANGELICA TRIAL, AND PROCEEDING TO DOSE LEVEL 2 IN PATIENTS WITH ADVANCED SOLID TUMORS OR HAEMATOLOGICAL MALIGNANCIES

  • CYTOMED THERAPEUTICS LTD - TO START DOSE LEVEL 2 IN ANGELICA TRIAL Q3 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI